Tevimbra-Tislelizumab-Jsgr
Tevimbra contains Tislelizumab, a monoclonal antibody that is indicated for the treatment of unresectable or metastatic small-cell lung cancer and gastric adenocarcinoma in adult patients. It can be given as a first line in combination with other chemotherapeutic agents, and also to patients who have previously received chemotherapy.
Winrevair-Sotatercept-Csrk
Winrevair is used to treat adults with pulmonary arterial hypertension (PAH). It helps improve exercise ability, daily functioning, and lowers the risk of the condition getting worse.
Bimzelx-Bimekizumab
Bimzelx is a subcutaneous injection used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis), and hidradenitis suppurativa. It targets and blocks IL‑17A and IL‑17F cytokines to reduce inflammation and skin/joint symptoms.
Omvoh-Mirikizumab-Mrkz
Omvoh is a once-daily oral antibody for adults with moderately to severely active ulcerative colitis. It targets inflammatory pathways to reduce bowel inflammation and improve symptoms.
Loqtorzi-Toripalimab-Tpzi
Loqtorzi is an IV antibody used alongside other treatments for recurrent or metastatic nasopharyngeal carcinoma. It helps the immune system recognize and attack cancer cells.
Ryzneuta-Efbemalenograstim Alfa-Vuxw
Ryzneuta is an injection that supports white blood cell production in cancer patients undergoing chemotherapy. It helps lower the risk of infection-related complications by boosting the immune system.
Niktimvo-Axatilimab-Csfr
Niktimvo is an IV antibody treatment for adults and children (≥ 40 kg) with chronic graft‑versus‑host disease whose condition worsened despite at least two prior therapies. It works by blocking CSF‑1R to calm overactive immune cells and reduce symptoms.
Ebglyss-Lebrikizumab-Lbkz
Ebglyss is used to treat moderate-to-severe atopic dermatitis. It addresses the inflammation caused by eczema all over your body, resulting in persistently dry, itchy, and irritated skin.
Hympavzi-Marstacimab-Hncq
Hympavzi is a subcutaneous antibody given to patients aged 12 and older to prevent bleeding episodes in hemophilia A or B without factor inhibitors. It works by inhibiting the tissue factor pathway to reduce the frequency of bleeds.
Nemluvio-Nemolizumab-Ilto
Nemluvio is an injectable antibody for adults suffering from debilitating itch in prurigo nodularis or moderate-to-severe atopic dermatitis. It blocks the IL‑31 receptor to reduce itching and improve skin healing, offering relief within 48 hours.
